Lexaria Bioscience Corp.
General ticker "LEXX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $22.0M (TTM average)
Lexaria Bioscience Corp. does not follow the US Stock Market performance with the rate: -18.2%.
Estimated limits based on current volatility of 5.8%: low 0.69$, high 0.77$
Factors to consider:
- Total employees count: 7 (+40.0%) as of 2024
- Top business risk factors: Product commercialization failure, Labor/talent shortage/retention, Market competition, Cybersecurity threats, Intellectual property risks
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-08-31 to 2027-08-31
- 2025-08-31 to 2026-08-31 estimated range: [0.61$, 1.66$]
- 2026-08-31 to 2027-08-31 estimated range: [0.56$, 1.52$]
Financial Metrics affecting the LEXX estimates:
- Positive: with PPE of -1.3 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -66.75 <= 0.04
- Positive: Shareholder equity ratio, % of 71.61 > 64.17
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term LEXX quotes
Long-term LEXX plot with estimates
Financial data
| YTD | 2023-08-31 | 2024-08-31 | 2025-08-31 |
|---|---|---|---|
| Operating Revenue | $0.23MM | $0.46MM | $0.71MM |
| Operating Expenses | $6.76MM | $6.22MM | $12.59MM |
| Operating Income | $-6.53MM | $-5.75MM | $-11.88MM |
| Non-Operating Income | $-0.18MM | $-0.06MM | $-0.02MM |
| R&D Expense | $3.67MM | $2.36MM | $8.24MM |
| Income(Loss) | $-6.71MM | $-5.81MM | $-11.90MM |
| Profit(Loss)* | $-6.66MM | $-5.80MM | $-11.89MM |
| Stockholders Equity | $3.04MM | $8.04MM | $2.99MM |
| Assets | $3.08MM | $8.87MM | $4.18MM |
| Operating Cash Flow | $-5.88MM | $-4.96MM | $-10.45MM |
| Capital expenditure | $0.17MM | $0.04MM | $0.00MM |
| Investing Cash Flow | $-0.17MM | $-0.19MM | $-0.24MM |
| Financing Cash Flow | $1.59MM | $10.30MM | $6.05MM |
| Earnings Per Share** | $-1.01 | $-0.47 | $-0.66 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.